Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Positive interim data from phase II trial of Allovectin-7 reported at ASCO

June 12, 2003

Manufacturing of CoFactor underway

June 10, 2003

Interim findings from ongoing phase I trial of OncoVEX(GM-CSF)

June 6, 2003

HER-2/neu vaccine enters phase I trial for breast cancer

June 6, 2003

Oncofetal protein validated as a potential target for lung cancer immunotherapy

June 6, 2003

EMD-72000 shows good tolerability and evidence of antitumor activity in phase I trials

June 5, 2003

Orphan drug status awarded to KSB-303 for pancreatic cancer

May 30, 2003

Safety phase of lactoferrin study completed

May 27, 2003

TroVax trial in renal cancer cleared to begin

May 22, 2003

Preliminary phase II Onyvax-P results

May 19, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...